189 related articles for article (PubMed ID: 37146419)
1. New findings on the action of hypericin in hypoxic cancer cells with a focus on the modulation of side population cells.
Buľková V; Vargová J; Babinčák M; Jendželovský R; Zdráhal Z; Roudnický P; Košuth J; Fedoročko P
Biomed Pharmacother; 2023 Jul; 163():114829. PubMed ID: 37146419
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.
He M; Wu H; Jiang Q; Liu Y; Han L; Yan Y; Wei B; Liu F; Deng X; Chen H; Zhao L; Wang M; Wu X; Yao W; Zhao H; Chen J; Wei M
Mol Oncol; 2019 Feb; 13(2):403-421. PubMed ID: 30536571
[TBL] [Abstract][Full Text] [Related]
3. Anterior gradient 2 promotes tumorigenesis through upregulation of CCAAT-enhancer binding protein beta and hypoxia-inducible factor-2α and subsequent secretion of interleukin-6, interleukin-8, and vascular endothelial growth factor in the Caki-1 clear cell renal cell carcinoma cell line.
Pajdzik K; Wilamowski M; Żurawek D; Stopa KB; Nodzyński M; Kalita A; Jura J
IUBMB Life; 2020 Aug; 72(8):1807-1818. PubMed ID: 32593213
[TBL] [Abstract][Full Text] [Related]
4. HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways.
Yan Y; Liu F; Han L; Zhao L; Chen J; Olopade OI; He M; Wei M
J Exp Clin Cancer Res; 2018 Oct; 37(1):256. PubMed ID: 30340507
[TBL] [Abstract][Full Text] [Related]
5. Hypericin affects cancer side populations via competitive inhibition of BCRP.
Vargová J; Mikeš J; Jendželovský R; Mikešová L; Kuchárová B; Čulka Ľ; Fedr R; Remšík J; Souček K; Kozubík A; Fedoročko P
Biomed Pharmacother; 2018 Mar; 99():511-522. PubMed ID: 29665654
[TBL] [Abstract][Full Text] [Related]
6. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
[TBL] [Abstract][Full Text] [Related]
7. The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion.
Koh MY; Lemos R; Liu X; Powis G
Cancer Res; 2011 Jun; 71(11):4015-27. PubMed ID: 21512133
[TBL] [Abstract][Full Text] [Related]
8. HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer.
Jarman EJ; Ward C; Turnbull AK; Martinez-Perez C; Meehan J; Xintaropoulou C; Sims AH; Langdon SP
Breast Cancer Res; 2019 Jan; 21(1):10. PubMed ID: 30670058
[TBL] [Abstract][Full Text] [Related]
9. Association of NRF2 with HIF-2α-induced cancer stem cell phenotypes in chronic hypoxic condition.
Hallis SP; Kim SK; Lee JH; Kwak MK
Redox Biol; 2023 Apr; 60():102632. PubMed ID: 36791645
[TBL] [Abstract][Full Text] [Related]
10. Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF-2α expression in lung cancer cells under normoxia and hypoxia.
Aquino-Gálvez A; González-Ávila G; Delgado-Tello J; Castillejos-López M; Mendoza-Milla C; Zúñiga J; Checa M; Maldonado-Martínez HA; Trinidad-López A; Cisneros J; Torres-Espíndola LM; Hernández-Jiménez C; Sommer B; Cabello-Gutiérrez C; Gutiérrez-González LH
Oncol Rep; 2016 Jan; 35(1):577-83. PubMed ID: 26548300
[TBL] [Abstract][Full Text] [Related]
11. Lenticular cytoprotection. Part 1: the role of hypoxia inducible factors-1α and -2α and vascular endothelial growth factor in lens epithelial cell survival in hypoxia.
Neelam S; Brooks MM; Cammarata PR
Mol Vis; 2013; 19():1-15. PubMed ID: 23335846
[TBL] [Abstract][Full Text] [Related]
12. Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy.
Barliya T; Mandel M; Livnat T; Weinberger D; Lavie G
PLoS One; 2011; 6(9):e22849. PubMed ID: 21949677
[TBL] [Abstract][Full Text] [Related]
13. Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation.
Mu H; Yu G; Li H; Wang M; Cui Y; Zhang T; Song T; Liu C
Cell Oncol (Dordr); 2021 Oct; 44(5):1151-1166. PubMed ID: 34339013
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer.
Kikuchi H; Pino MS; Zeng M; Shirasawa S; Chung DC
Cancer Res; 2009 Nov; 69(21):8499-506. PubMed ID: 19843849
[TBL] [Abstract][Full Text] [Related]
15. HIF-1α and HIF-2α correlate with migration and invasion in gastric cancer.
Wang Y; Li Z; Zhang H; Jin H; Sun L; Dong H; Xu M; Zhao P; Zhang B; Wang J; Pan Y; Liu L
Cancer Biol Ther; 2010 Aug; 10(4):376-82. PubMed ID: 20559021
[TBL] [Abstract][Full Text] [Related]
16. CD44 Interacts with HIF-2α to Modulate the Hypoxic Phenotype of Perinecrotic and Perivascular Glioma Cells.
Johansson E; Grassi ES; Pantazopoulou V; Tong B; Lindgren D; Berg TJ; Pietras EJ; Axelson H; Pietras A
Cell Rep; 2017 Aug; 20(7):1641-1653. PubMed ID: 28813675
[TBL] [Abstract][Full Text] [Related]
17. Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers.
Bobarykina AY; Minchenko DO; Opentanova IL; Moenner M; Caro J; Esumi H; Minchenko OH
Acta Biochim Pol; 2006; 53(4):789-99. PubMed ID: 17143338
[TBL] [Abstract][Full Text] [Related]
18. Increased activation of the hypoxia-inducible factor pathway in varicose veins.
Lim CS; Kiriakidis S; Paleolog EM; Davies AH
J Vasc Surg; 2012 May; 55(5):1427-39. PubMed ID: 22277691
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells.
He X; Wang J; Wei W; Shi M; Xin B; Zhang T; Shen X
Cancer Biol Ther; 2016; 17(2):188-98. PubMed ID: 26785721
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-induced lncRNA ANRIL promotes cisplatin resistance in retinoblastoma cells through regulating ABCG2 expression.
Yin X; Liao Y; Xiong W; Zhang Y; Zhou Y; Yang Y
Clin Exp Pharmacol Physiol; 2020 Jun; 47(6):1049-1057. PubMed ID: 32173903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
